30 closest matches · ranked by relevance
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months
High Grade Glioma
Primary: Response Rate
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival — 3 percent
Brain Cancer
Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants
Newly Diagnosed Glioblastoma
Primary: Overall Survival (OS) — 16.13; 15.08 Months
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Glioblastoma · Gliosarcoma · Supratentorial Glioblastoma
Primary: Overall Survival (OS) — 16.1; 15.7 months — p=0.11
Glioblastoma
Primary: Concentration of Ixazomib in Tumor Tissue — 7.88; 2.03; 4.17; 2.70 ng/g
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants
Glioblastoma Multiforme
Primary: Objective Response Rate (ORR) — 17.6; 27.0; 8.8; 8.3 percentage of participants
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 5.7 months — p=0.4
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.1 months
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival (PFS) — 0; 5 percentage of patients
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Glioblastoma
Primary: Number of Patients With Adverse Events — 35 Participants
Glioblastoma Multiforme · Glioblastoma · Malignant Glioma
Primary: Comparison of Overall Survival (OS) Between the Active Treatment Group (Arms 1 and 2) and the Control Group (Arm 3) — 16.9; 16.2; 20.6 months — p=0.196
Glioblastoma Multiforme
Primary: Survival — 17.2 months — p=>.1
Brain and Central Nervous System Tumors
Primary: Phase I: Number of Patients With Dose-limiting Toxicity (DLT) — 2; 2; 2 Participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 9.33; 7.62 Months
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Glioblastoma
Primary: Overall Survival at 12 Months (OS12) — 72.7 percentage of participants